1-4 of 4
Bailey Slawin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2023) 142 (Supplement 1): 4195.
https://doi.org/10.1182/blood-2023-188250
Published: 2023
Journal Articles

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Jyotsana Singh, John R. Sanchez II, Chaomei Liu, Bailey Slawin, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, James S. Blachly, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2023) 142 (Supplement 1): 2283.
https://doi.org/10.1182/blood-2023-189378
Published: 2023
Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2022) 140 (Supplement 1): 497–498.
https://doi.org/10.1182/blood-2022-168345
Published: 2022
Journal Articles

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Jyotsana Singh, Daisy Diaz Rohena, Chaomei Liu, Bailey Slawin, Janani Ravikrishnan, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2022) 140 (Supplement 1): 9857–9858.
https://doi.org/10.1182/blood-2022-168391
Published: 2022